Brookhaven Lab Mobilizes Resources in Fight Against COVID-19

April 6, 2020

UPTON, N.Y., April 6, 2020 — Scientists and staff at the U.S. Department of Energy’s (DOE) national laboratories are marshaling their expertise, unique facilities, and other key resources in the battle against COVID-19. At Brookhaven National Laboratory:

  • Research is already underway to better understand key characteristics of the virus that causes COVID-19 and its interactions with human cells, which could help guide the development of therapeutic drugs and vaccines.
  • Laboratory scientists and collaborators are using experiments and computational methods to identify the most promising drug/vaccine candidates, and developing tools to help other scientists keep up with the latest developments around the world.
  • The Laboratory has also gathered critical protective equipment as part of a Federal effort to support medical professionals, and is exploring options for making much-needed supplies.
Brookhaven researchers are marshaling experimental capabilities and computational resources in the fight against the COVID-19 pandemic. Image courtesy of Brookhaven National Laboratory.

“Brookhaven Lab has exceptional resources for addressing some of the most urgent scientific and logistical challenges of this pandemic,” said John Hill, director of Brookhaven Lab’s National Synchrotron Light Source II (NSLS-II), who is chairing a working group to coordinate the Lab’s COVID-19 science and technology efforts, and is serving on a team coordinating the COVID-19 research across all the DOE national labs.

“The speed with which the entire scientific community is attacking this problem is amazing,” he said, “and the whole Lab, whether working off site or on, is part of this effort.”

Deciphering protein structures

Even as the Laboratory operates with minimal staff to help keep the virus from spreading, experiments are running at two of NSLS-II’s protein crystallography beamlines to help find ways to thwart the virus. These experiments aim to characterize the atomic-level structure of viral components, including how they connect with receptors on human cells, so scientists can identify ways to block the infection-causing interactions.

NSLS-II, a DOE Office of Science user facility, provides x-ray beams to create those atomic-scale pictures.

These images represent protein structures related to COVID-19 that have been solved at synchrotrons around the world and deposited in the Protein Data Bank. Studies continue at those facilities and at Brookhaven’s NSLS-II to decipher the details of the viral proteins and their interactions with human cells in an effort to develop antiviral drugs and vaccines. (a) 6LU7, (b) 6W41, (c) 6VYO  Image courtesy of RCSB Protein Data Bank.

“NSLS-II has the brightest synchrotron x-rays in the world for studying the proteins in the virus and understanding better the processes hijacked in infected cells,” said Sean McSweeney, leader of Brookhaven Lab’s structural biology program. “The high brightness means we can get ‘pictures’ from tiny crystal samples of the proteins. We don’t need to spend weeks, or months, growing big crystals, which is typically a bottleneck in protein crystallography. We also have methods for testing potential drugs that bind to these proteins and then collecting and sifting through data very rapidly—all of which greatly speed the process of discovery.”

Scientists from several pharmaceutical companies and academic researchers have already collected data, and more are expected each week, in some cases collaborating in the search for antiviral agents and targets for vaccines. Brookhaven scientists are engaged in this work as well.

“One group, which includes scientists from the biology department, is working to solve the structure of an ‘envelope’ protein embedded in the virus’s membrane. This protein is important to the virus’s life cycle,” McSweeney said. “Deciphering these structures will provide atomic-level data that could guide the development of drugs that bind to the proteins and interfere with their functions so the virus can no longer infect cells or replicate.”

The structural studies may help identify viral components that are most likely to trigger the production of antibodies—chemicals produced by the immune system that can fight off an infection. These immune-system-triggering proteins, known as antigens, form the basis of most vaccines.

“The Department of Energy has been exceptionally helpful in fast-tracking the approval process for this research,” Hill said. “Every proposal is getting beamtime.”

Much of the data will be published in the open research literature and deposited in the globally accessible Protein Data Bank so that scientists everywhere can learn from one another and build on each other’s efforts.  Brookhaven is also hosting a centralized portal to streamline access to all the structural biology resources across the DOE complex.

Brookhaven is also fielding requests to pursue COVID-19 protein studies at its new cryo-electron microscopy (cryoEM) facility—the Laboratory of BioMolecular Structure—which is currently under construction adjacent to NSLS-II.

“The Laboratory and DOE both recognize how crucial this facility will be to advancing our understanding of COVID-19, particularly for studying the large protein complexes that span cell membranes,” said Hill. “We are so grateful to everyone who is working to bring this facility into operation at an accelerated pace.”

Computational approaches

Once scientists know the viral components they want to target for developing therapeutic agents, they need to know which small drug-like molecules will fit into the viral-protein pockets or the cell-surface receptors to which the virus binds. Brookhaven scientists are working on that piece of the puzzle, too.

NSLS-II, for example, can run experiments using samples of viral or receptor proteins and drug candidates together to find which fit best and offer the most promise of blocking infection.

Scientists are using supercomputing resources at Brookhaven and across the U.S. to screen the chemical structures of a wide range of small molecules that might be able to block key viral functions. Image courtesy of Brookhaven National Laboratory.

But the universe of small molecules that could interact with protein components is extremely large. Running experiments to look at every possibility would take far too long.

Fortunately, computational scientists at Brookhaven, working in partnership with colleagues at Stony Brook University, Argonne National Laboratory (ANL), Rutgers University, Oak Ridge National Laboratory (ORNL), the University of Texas, and elsewhere—currently around 160 scientists, 25 at Brookhaven—are helping to speed up the search for drugs.

“The aim of this research is to accelerate the development of antiviral drugs by modeling proteins that play critical roles in the virus life cycle to identify promising drug targets,” said Kerstin Kleese van Dam, director of Brookhaven Lab’s Computational Science Initiative (CSI).

Using supercomputing resources across the U.S., the scientists will screen the chemical structures of a wide range of small molecules that might be able to block key viral functions. These “virtual” experiments will explore the chemical structures of known drugs that are already licensed and could quickly be repurposed, as well as libraries of small drug-like molecules that could be developed into drugs. Brookhaven scientists are focused on large-scale libraries with billions of chemical structures that could be manufactured quickly for testing.

This research relies on machine learning and other tools of artificial intelligence (AI) running simulations of the interactions between proteins and potential drugs. The virtual screening using these “molecular dynamics” simulations will refine the machine learning and AI approaches so that successive rounds of evaluations create a list of potentially viable small-molecule drug candidates.

As one local example, in a project led by Stony Brook, Lab scientists will be running simulations to see which molecules might block the interaction between the “crown” (or corona) of “spike” proteins on the COVID-19 virus and receptors on human lung cells.

This image shows how the “spike” protein on the virus that causes COVID-19 binds to a receptor protein on the surface of cells that line the human respiratory system (cell membrane shown in green and red at bottom). Understanding how the spike (made of three proteins, red, yellow, and blue) binds with the receptor (angiotensin-converting enzyme 2, or ACE2, purple), and modeling how different molecules might interfere with this interaction, could help scientists develop antiviral drugs. Image courtesy of  SBU Professor Carlos Simmerling and SBU graduate student Lucy Fallon. 

“In a first step, we will be looking at 60 different target sites where a new drug may attach to the virus and one billion drug-like molecules to identify the most promising options for neutralizing the virus to keep it from entering cells,” Kleese van Dam said. Then, only those particularly promising molecules would need to be studied in detail with structural studies at synchrotrons like NSLS-II or cryo-EM facilities.

Kleese van Dam put out a call for volunteers across the Lab who have experience with high performance computing and the Lab’s computing clusters to help make faster progress, saying “We have the data, we have the tools, but need people who can help us to run the programs and check that they ran correctly, and to test an initial set of structures against possible drug targets.”

The response was overwhelming. “We had very quickly a large number of volunteers—more than we could accommodate on our current project—from all across the Lab, including staff from NSLS-II, the Center for Functional Nanomaterials (CFN), high-energy and nuclear physics, and the Collider-Accelerator Department,” Kleese van Dam said.

Many scientists at the Lab’s Office of Science user facilities—which include CFN and the Relativistic Heavy Ion Collider (RHIC) in addition to NSLS-II—have experience dealing with “big data” problems, so this call-to-action was a perfect fit.

“I’m so grateful to those who stepped up so selflessly,” Kleese van Dam said. “We’re compiling a list of all these volunteers so we can deploy them to a range of COVID-19 projects as needed going forward.”

Kleese van Dam’s group is also developing computational tools to help scientists battling COVID-19 keep up with the latest research developments around the world.

“More than 15,000 new papers related to COVID-19 have been published since the start of the outbreak in December 2019, and the quality and relevance of these papers to current research needs varies dramatically,” she said. “We’re developing a ‘natural language processing’ program that will search through a library of all these papers to pull out the most relevant information based on a researcher’s plain-language question.” Using this system, scientists would be able to more easily find and track the latest data on which drugs are in clinical trials, for example, or pull out research on the latest potential targets.

A different kind of computational model developed with help from Brookhaven scientists was designed to simulate the spread of the virus in the Chicago area. This project was led by Sergei Maslov, a former Brookhaven scientist who is now at the University of Illinois at Urbana Champaign and is still a CFN user, with help from CFN’s Alexei Tkachenko. Government officials in Illinois used this model in an early effort to optimize their response to the outbreak there, and ongoing research continues to improve and extend this work.

For the full article and additional graphics, visit https://www.bnl.gov/newsroom/news.php?a=117162.

About Brookhaven National Laboratory

Brookhaven National Laboratory is supported by the U.S. Department of Energy’s Office of Science. The Office of Science is the single largest supporter of basic research in the physical sciences in the United States and is working to address some of the most pressing challenges of our time. For more information, visit https://www.energy.gov/science/


Source: Brookhaven National Laboratory

Subscribe to HPCwire's Weekly Update!

Be the most informed person in the room! Stay ahead of the tech trends with industry updates delivered to you every week!

MLPerf Inference 4.0 Results Showcase GenAI; Nvidia Still Dominates

March 28, 2024

There were no startling surprises in the latest MLPerf Inference benchmark (4.0) results released yesterday. Two new workloads — Llama 2 and Stable Diffusion XL — were added to the benchmark suite as MLPerf continues Read more…

Q&A with Nvidia’s Chief of DGX Systems on the DGX-GB200 Rack-scale System

March 27, 2024

Pictures of Nvidia's new flagship mega-server, the DGX GB200, on the GTC show floor got favorable reactions on social media for the sheer amount of computing power it brings to artificial intelligence.  Nvidia's DGX Read more…

Call for Participation in Workshop on Potential NSF CISE Quantum Initiative

March 26, 2024

Editor’s Note: Next month there will be a workshop to discuss what a quantum initiative led by NSF’s Computer, Information Science and Engineering (CISE) directorate could entail. The details are posted below in a Ca Read more…

Waseda U. Researchers Reports New Quantum Algorithm for Speeding Optimization

March 25, 2024

Optimization problems cover a wide range of applications and are often cited as good candidates for quantum computing. However, the execution time for constrained combinatorial optimization applications on quantum device Read more…

NVLink: Faster Interconnects and Switches to Help Relieve Data Bottlenecks

March 25, 2024

Nvidia’s new Blackwell architecture may have stolen the show this week at the GPU Technology Conference in San Jose, California. But an emerging bottleneck at the network layer threatens to make bigger and brawnier pro Read more…

Who is David Blackwell?

March 22, 2024

During GTC24, co-founder and president of NVIDIA Jensen Huang unveiled the Blackwell GPU. This GPU itself is heavily optimized for AI work, boasting 192GB of HBM3E memory as well as the the ability to train 1 trillion pa Read more…

MLPerf Inference 4.0 Results Showcase GenAI; Nvidia Still Dominates

March 28, 2024

There were no startling surprises in the latest MLPerf Inference benchmark (4.0) results released yesterday. Two new workloads — Llama 2 and Stable Diffusion Read more…

Q&A with Nvidia’s Chief of DGX Systems on the DGX-GB200 Rack-scale System

March 27, 2024

Pictures of Nvidia's new flagship mega-server, the DGX GB200, on the GTC show floor got favorable reactions on social media for the sheer amount of computing po Read more…

NVLink: Faster Interconnects and Switches to Help Relieve Data Bottlenecks

March 25, 2024

Nvidia’s new Blackwell architecture may have stolen the show this week at the GPU Technology Conference in San Jose, California. But an emerging bottleneck at Read more…

Who is David Blackwell?

March 22, 2024

During GTC24, co-founder and president of NVIDIA Jensen Huang unveiled the Blackwell GPU. This GPU itself is heavily optimized for AI work, boasting 192GB of HB Read more…

Nvidia Looks to Accelerate GenAI Adoption with NIM

March 19, 2024

Today at the GPU Technology Conference, Nvidia launched a new offering aimed at helping customers quickly deploy their generative AI applications in a secure, s Read more…

The Generative AI Future Is Now, Nvidia’s Huang Says

March 19, 2024

We are in the early days of a transformative shift in how business gets done thanks to the advent of generative AI, according to Nvidia CEO and cofounder Jensen Read more…

Nvidia’s New Blackwell GPU Can Train AI Models with Trillions of Parameters

March 18, 2024

Nvidia's latest and fastest GPU, codenamed Blackwell, is here and will underpin the company's AI plans this year. The chip offers performance improvements from Read more…

Nvidia Showcases Quantum Cloud, Expanding Quantum Portfolio at GTC24

March 18, 2024

Nvidia’s barrage of quantum news at GTC24 this week includes new products, signature collaborations, and a new Nvidia Quantum Cloud for quantum developers. Wh Read more…

Alibaba Shuts Down its Quantum Computing Effort

November 30, 2023

In case you missed it, China’s e-commerce giant Alibaba has shut down its quantum computing research effort. It’s not entirely clear what drove the change. Read more…

Nvidia H100: Are 550,000 GPUs Enough for This Year?

August 17, 2023

The GPU Squeeze continues to place a premium on Nvidia H100 GPUs. In a recent Financial Times article, Nvidia reports that it expects to ship 550,000 of its lat Read more…

Shutterstock 1285747942

AMD’s Horsepower-packed MI300X GPU Beats Nvidia’s Upcoming H200

December 7, 2023

AMD and Nvidia are locked in an AI performance battle – much like the gaming GPU performance clash the companies have waged for decades. AMD has claimed it Read more…

DoD Takes a Long View of Quantum Computing

December 19, 2023

Given the large sums tied to expensive weapon systems – think $100-million-plus per F-35 fighter – it’s easy to forget the U.S. Department of Defense is a Read more…

Synopsys Eats Ansys: Does HPC Get Indigestion?

February 8, 2024

Recently, it was announced that Synopsys is buying HPC tool developer Ansys. Started in Pittsburgh, Pa., in 1970 as Swanson Analysis Systems, Inc. (SASI) by John Swanson (and eventually renamed), Ansys serves the CAE (Computer Aided Engineering)/multiphysics engineering simulation market. Read more…

Choosing the Right GPU for LLM Inference and Training

December 11, 2023

Accelerating the training and inference processes of deep learning models is crucial for unleashing their true potential and NVIDIA GPUs have emerged as a game- Read more…

Intel’s Server and PC Chip Development Will Blur After 2025

January 15, 2024

Intel's dealing with much more than chip rivals breathing down its neck; it is simultaneously integrating a bevy of new technologies such as chiplets, artificia Read more…

Baidu Exits Quantum, Closely Following Alibaba’s Earlier Move

January 5, 2024

Reuters reported this week that Baidu, China’s giant e-commerce and services provider, is exiting the quantum computing development arena. Reuters reported � Read more…

Leading Solution Providers

Contributors

Comparing NVIDIA A100 and NVIDIA L40S: Which GPU is Ideal for AI and Graphics-Intensive Workloads?

October 30, 2023

With long lead times for the NVIDIA H100 and A100 GPUs, many organizations are looking at the new NVIDIA L40S GPU, which it’s a new GPU optimized for AI and g Read more…

Shutterstock 1179408610

Google Addresses the Mysteries of Its Hypercomputer 

December 28, 2023

When Google launched its Hypercomputer earlier this month (December 2023), the first reaction was, "Say what?" It turns out that the Hypercomputer is Google's t Read more…

AMD MI3000A

How AMD May Get Across the CUDA Moat

October 5, 2023

When discussing GenAI, the term "GPU" almost always enters the conversation and the topic often moves toward performance and access. Interestingly, the word "GPU" is assumed to mean "Nvidia" products. (As an aside, the popular Nvidia hardware used in GenAI are not technically... Read more…

Shutterstock 1606064203

Meta’s Zuckerberg Puts Its AI Future in the Hands of 600,000 GPUs

January 25, 2024

In under two minutes, Meta's CEO, Mark Zuckerberg, laid out the company's AI plans, which included a plan to build an artificial intelligence system with the eq Read more…

Google Introduces ‘Hypercomputer’ to Its AI Infrastructure

December 11, 2023

Google ran out of monikers to describe its new AI system released on December 7. Supercomputer perhaps wasn't an apt description, so it settled on Hypercomputer Read more…

China Is All In on a RISC-V Future

January 8, 2024

The state of RISC-V in China was discussed in a recent report released by the Jamestown Foundation, a Washington, D.C.-based think tank. The report, entitled "E Read more…

Intel Won’t Have a Xeon Max Chip with New Emerald Rapids CPU

December 14, 2023

As expected, Intel officially announced its 5th generation Xeon server chips codenamed Emerald Rapids at an event in New York City, where the focus was really o Read more…

IBM Quantum Summit: Two New QPUs, Upgraded Qiskit, 10-year Roadmap and More

December 4, 2023

IBM kicks off its annual Quantum Summit today and will announce a broad range of advances including its much-anticipated 1121-qubit Condor QPU, a smaller 133-qu Read more…

  • arrow
  • Click Here for More Headlines
  • arrow
HPCwire